Taghavi Sahar, Nia Azadeh Hashem, Abnous Khalil, Ramezani Mohammad
Pharmaceutical Research Center, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
Pharmaceutical Research Center, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
Int J Pharm. 2017 Jan 10;516(1-2):301-312. doi: 10.1016/j.ijpharm.2016.11.027. Epub 2016 Nov 10.
In this project, synergistic cancer cell death was achieved by a targeted delivery system comprising Bcl-xL-specific shRNA and a very low DOX content, which simultaneously activated an intrinsic apoptotic pathway. A modified branched polyethylenimine (PEI 10kDa) was grafted through polyethylene glycol (PEG) linker to carboxylated single-walled carbon nanotubes (SWCNT) to serve as a vehicle for shRNA delivery. The SWNT-PEG-PEI conjugate was covalently attached to AS1411 aptamer as the nucleolin ligand to target the co-delivery system to the tumor cells overexpressing nucleolin receptors on their surface. The final vehicle was eventually obtained after intercalation of DOX with pBcl-xL shRNA-SWCNT-PEG-10-10%PEI-Apt. Cell viability assay, GFP expression and transfection experiment against L929 (-nucleolin) and AGS (+nucleolin) cells illustrated that the tested targeted delivery system inhibited the growth of nucleolin-abundant gastric cancer cells with strong cell selectivity. Subsequently, we illustrated that the combination treatment of the selected shRNAs and DOX had excellent tumoricidal efficacy as verified by MTT assay. Furthermore, very low concentration of DOX, approximately 58-fold lower than its IC50 concentration, was used which could mitigate toxic side effects of DOX. Overall, our work revealed that combination of shRNA-mediated gene-silencing strategy with chemotherapeutic agents constitutes a valuable and safe approach for antitumor activity.
在本项目中,通过一个包含Bcl-xL特异性短发夹RNA(shRNA)和极低阿霉素(DOX)含量的靶向递送系统实现了协同癌细胞死亡,该系统同时激活了内源性凋亡途径。一种经过修饰的支化聚乙烯亚胺(10 kDa PEI)通过聚乙二醇(PEG)连接子接枝到羧基化单壁碳纳米管(SWCNT)上,作为shRNA递送的载体。SWNT-PEG-PEI偶联物与AS1411适配体共价连接,作为核仁素配体,将共递送系统靶向到其表面过表达核仁素受体的肿瘤细胞。在将DOX与pBcl-xL shRNA-SWCNT-PEG-10-10%PEI-Apt进行插层后,最终获得了最终载体。针对L929(-核仁素)和AGS(+核仁素)细胞的细胞活力测定、绿色荧光蛋白(GFP)表达和转染实验表明,所测试的靶向递送系统具有很强的细胞选择性,可抑制富含核仁素的胃癌细胞的生长。随后,我们通过MTT测定法证实,所选shRNA与DOX的联合治疗具有优异的杀肿瘤效果。此外,使用的DOX浓度非常低,比其半数抑制浓度(IC50)低约58倍,这可以减轻DOX的毒副作用。总体而言,我们的工作表明,shRNA介导的基因沉默策略与化疗药物的联合构成了一种有价值且安全的抗肿瘤活性方法。
Expert Opin Drug Deliv. 2018-10-5
Cancers (Basel). 2025-2-27
Mater Today Bio. 2025-1-4
Biotechnol Rep (Amst). 2024-5-24
Materials (Basel). 2022-8-5